MS Center at Evergreen

Kirkland, Washington 98101

0 studies enrolling now · 9 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Clinically Isolated Syndrome, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis

Studies at this site

• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants — Completed
• A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis — Completed
• Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis — Stopped early
• Study of Fampridine-SR Tablets in Multiple Sclerosis Patients — Completed
• Autologous T Cell Vaccine (TCV) for Multiple Sclerosis — Completed
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis — Completed
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial — Completed
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial — Completed
• Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis — Status unconfirmed